Published within
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
A study has suggested that the mortality risk posed by stent thrombosis is increased five-fold for STEMI patients receiving drug-eluting stents, compared to bare-metal stents. If proven, stent development is likely to move away from new drug-coated stents allowing smaller companies a chance to compete with leading players such as Boston Scientific and Johnson & Johnson.
Published By Datamonitor
|
06 Sep 2007 |
|
Expert View
|
Well crafted, positive results for AstraZeneca's Brilinta and an unexpected coup for Boehringer Ingelheim's Pradaxa dominated the headlines following this year's European Society of Cardiology's Annual Meeting in Barcelona. Both announcements have a number of important implications for the wider cardiology market, from both therapeutic and commercial perspectives.
Published By Datamonitor
|
03 Sep 2009 |
|
Expert View
|
Datamonitor attended this year's meeting of the American Thoracic Society in New Orleans. The 2010 conference was defined not only by the latest clinical trial data, but by new guidelines and an emerging discussion of the role of personalized treatment. Conclusions were also presented from the ISAAC study, highlighting some surprising global prevalence trends.
Published By Datamonitor
|
04 Jun 2010 |
|
Expert View
|
The FDA's recent refusal of Esbriet and the publication of new guidelines for the treatment of idiopathic pulmonary fibrosis drove considerable interest in this disease at the 2010 meeting of the American Thoracic Society. Furthermore, the approval of the first new inhaled antibiotic for cystic fibrosis in over a decade brought renewed focus on this rare but extremely debilitating disease.
Published By Datamonitor
|
04 Jun 2010 |
|
Expert View
|
Key themes presented in the field of major depressive disorder at this year's American Psychiatric Association annual meeting included treatment-resistant depression, transcranial magnetic stimulation and adjunctive use of antipsychotics. While no new clinical trial data were presented, those that were provide an interesting insight into the strategies of a number of major pharmaceutical players.
Published By Datamonitor
|
10 Jun 2010 |
|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.